BioCryst regulatory update

BioCryst Pharmaceuticals Inc. The FDA granted Orphan Drug Designation to BioCryst's BCX-34, a topical treatment for cutaneous T-Cell lymphoma. BCX-34, BioCryst's first drug in development, controls p...